MetaCap

Kiniksa Pharmaceuticals International (KNSA) vs Madrigal Pharmaceuticals (MDGL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kiniksa Pharmaceuticals International (KNSA) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 125.8% versus a loss of 30.8%. Over five years, KNSA leads with a +706.0% price change compared with +362.0% for MDGL. Madrigal Pharmaceuticals is the larger company by market cap ($8.81 billion vs $7.38 billion), about 1.2 times the size.

On valuation, Madrigal Pharmaceuticals trades at a lower forward P/E (36.5x vs 45.9x for Kiniksa Pharmaceuticals International). Kiniksa Pharmaceuticals International converts more of its revenue into profit, with a net margin of 8.7% versus -30.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KNSA+125.82%MDGL-30.82%
+146%+53%-39%
Nov 21, 20251 yearNov 20, 2026
KNSA+669.63%MDGL+360.07%
+726%+328%-71%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KNSA versus MDGL key metrics
MetricKNSAMDGL
Share price$93.90$379.10
Market cap$7.38B$8.81B
1-day change+0.38%-4.45%
YTD return+127.62%-34.90%
1-year return+125.82%-30.82%
5-year return+705.97%+361.98%
P/E ratio (TTM)71.13—
Forward P/E45.9136.52
EPS (TTM)$1.32$-5.85
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$677.56M$958.40M
Revenue growth (YoY)+60.09%+432.05%
Net income (latest FY)$59.01M$-288.28M
Gross margin88.54%—
Operating margin11.40%-31.31%
Net margin8.71%-30.08%
52-week high$99.31$615.00
52-week low$37.02$353.54
Distance from 52-week high-5.45%-38.36%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+18.82%+81.69%
Average volume664.53K370.07K
Shares outstanding48.84M23.23M
Employees366915
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KNSA has outperformed MDGL by 156.6 percentage points over the past year.
  • Kiniksa Pharmaceuticals International is more profitable, keeping 8.7 cents of every revenue dollar as net income versus -30.1 cents for Madrigal Pharmaceuticals.
  • Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs +60.09%).

About Kiniksa Pharmaceuticals International

KNSA stock →

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees

About Madrigal Pharmaceuticals

MDGL stock →

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.

Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees

KNSA vs MDGL FAQ

Which is bigger, Kiniksa Pharmaceuticals International or Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (MDGL) is larger, with a market capitalization of $8.81B compared with $7.38B for Kiniksa Pharmaceuticals International (KNSA).

Which stock has performed better over the past year, KNSA or MDGL?

KNSA returned +125.82% over the past 12 months, compared with -30.82% for MDGL (price return, excluding dividends). Past performance does not predict future results.

Are Kiniksa Pharmaceuticals International and Madrigal Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons